Holen Sie sich die Stockscreener-App
1.815
5.20%
0.085
Schlusskurs vom Vortag:
$1.73
Offen:
$1.74
24-Stunden-Volumen:
1.73M
Relative Volume:
1.45
Marktkapitalisierung:
$125.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-89.66M
KGV:
-0.7498
EPS:
-2.4205
Netto-Cashflow:
$-81.90M
1W Leistung:
-56.97%
1M Leistung:
-67.99%
6M Leistung:
-63.31%
1J Leistung:
+66.21%
1-Tages-Spanne:
$1.66
$1.845
1-Wochen-Bereich:
$1.32
$2.0799
52-Wochen-Spanne:
$0.8801
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Firmenname
Pepgen Inc
Sektor
Branche
Telefon
703-456-8000
Adresse
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.815 | 119.57M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.14 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Eingeleitet | Guggenheim | Buy |
| 2024-12-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-07-31 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-21 | Eingeleitet | H.C. Wainwright | Buy |
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - ChartMill
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Assay what? Eyes on Pepgen’s DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - tipranks.com
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener
PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget
PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - biospace.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - globenewswire.com
A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com
Why PEPG, SGMO, PHR are among top premarket losers today - MSN
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - tipranks.com
Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - marketscreener.com
Why Is PepGen Stock Sinking Tuesday?PepGen (NASDAQ:PEPG) - Benzinga
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - BioSpace
PepGen reports ‘promising’ topline results from MAD cohort - TipRanks
PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada
Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - tipranks.com
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - au.investing.com
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView
[8-K] PepGen Inc. Reports Material Event - Stock Titan
PepGen stock tumbles 44% on disappointing trial results - Investing.com
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing - investing.com
PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way - Traders Union
PepGen, Inc. (NASDAQ:PEPG) Short Interest Up 26.1% in March - MarketBeat
PEPG.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
S P Trends: Is PepGen Inc stock a smart retirement pick2026 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
Swing Trade: Why is PepGen Inc stock going downLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
US FDA puts partial clinical hold on PepGen's muscle disease drug trial - MSN
If You Invested $1,000 in PepGen Inc (PEPG) - Stock Titan
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PEPG SEC FilingsPepGen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
COMMODORE CAPITAL LP Acquires Additional Shares in PepGen Inc - GuruFocus
Finanzdaten der Pepgen Inc-Aktie (PEPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pepgen Inc-Aktie (PEPG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Donnelly Noel | Chief Financial Officer |
Mar 04 '26 |
Sale |
6.23 |
2,084 |
12,988 |
111,603 |
| McArthur James G | President and CEO |
Mar 04 '26 |
Sale |
6.23 |
5,275 |
32,876 |
296,326 |
| Oxford Science Enterprises plc | Former 10% Owner |
Sep 30 '25 |
Buy |
3.20 |
200,000 |
640,000 |
4,955,388 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Sep 26 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
18,554,273 |
| STRECK PAUL | EVP, Head of R&D |
May 30 '25 |
Buy |
1.24 |
8,375 |
10,393 |
27,805 |
| McArthur James G | President and CEO |
Apr 17 '25 |
Buy |
1.35 |
10,000 |
13,550 |
113,913 |
| McArthur James G | President and CEO |
Apr 08 '25 |
Buy |
1.15 |
41,500 |
47,725 |
103,913 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):